Dermata Therapeutics (NASDAQ:DRMA – Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.55) earnings per share (EPS) for the quarter, FiscalAI reports. The company had revenue of $0.07 million for the quarter.
Dermata Therapeutics Price Performance
Shares of DRMA stock traded down $0.06 during trading hours on Tuesday, hitting $0.71. The stock had a trading volume of 45,058 shares, compared to its average volume of 1,639,901. Dermata Therapeutics has a twelve month low of $0.60 and a twelve month high of $4.66. The firm has a market capitalization of $3.54 million, a PE ratio of -0.16 and a beta of 0.63. The stock’s 50 day moving average is $1.01 and its 200 day moving average is $1.28.
Analyst Ratings Changes
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Dermata Therapeutics in a report on Monday, October 26th. One investment analyst has rated the stock with a Sell rating. According to MarketBeat.com, Dermata Therapeutics presently has an average rating of “Sell”.
View Our Latest Report on Dermata Therapeutics
Dermata Therapeutics Company Profile
Dermata Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for dermatological diseases. The company’s research is centered on topical therapies intended to address common inflammatory and dermatologic conditions. Its lead product candidate, DMT310, is a once-weekly topical treatment being evaluated for conditions including psoriasis and acne vulgaris. The therapy is based on a proprietary platform derived from a naturally occurring freshwater sponge and is designed to deliver localized treatment to the skin.
Read More
- Five stocks we like better than Dermata Therapeutics
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for Dermata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
